Civica
Address: 2912 W Executive Pkwy, Lehi, Utah.About Us
We are partnering with hospitals and healthcare systems to
(1) prioritize production of generic drugs and
(2) purchase Civica generic drugs, based on hospital systems’ clinical needs.
- We are creating market stability by procuring or manufacturing the products required by our hospital systems
- We are guaranteeing volumes for our hospitals and health system partners for each drug we manufacture
Sectors
- Generic Formulations
- Collaborations & Partnerships-Services
Categories
- Generic Formulations
- Finished Dosage
- Insulin Products
- Hospital Products
- Diabetes
News
Biocon Biologics and Civica, Inc. collaborate to expand insulin Aspart access in US
Bengaluru-based Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, and Civica, Inc., a not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, have announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States (US).
Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia. Civica will commercialise the medicine for patients in the United States, after completion of development work and clinical trials. No technology transfer is involved in the agreement.
This collaboration is in addition to Biocon Biologics’ own Insulin Aspart Drug Product for the United States which is currently under US Food and Drug Administration (FDA) review.
There are 38.4 million people with diabetes in the United States, approximately 11.6 percent of the total population, with nearly a quarter being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic.
California Selects Civica Rx as Its Insulin Manufacturing Partner
LEHI, UTAH, March 18, 2023 – Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work. Once approved, Civica’s biosimilar versions of the most commonly used short-and long-acting insulins will be available to Californians and nationwide at significantly lower prices than insulins currently on the market. The availability of these insulins will benefit Californians with diabetes who have been forced to choose between life sustaining medicines and living expenses.
Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
Civica announced previously that it intends to produce three insulin biosimilars—glargine, lispro and aspart. The products will be available both in vials and prefilled pens.
AmerisourceBergen Kicks Off Strategic Relationship with Civica
Conshohocken, Pa., January 23, 2023 – Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members. Through its distribution network, AmerisourceBergen will work to ensure that Civica’s crucial products reach its members across the country efficiently, reliably, and securely.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com